



FINCH 2 vs SELECT-BEYOND

FINCH 2

Event type	filgotinib, 24-week period # of events	
	100 mg QD	200 mg QD
dose		
N	153	148
SAEs	8	6
opportunistic infections	-	-
herpes zoster	2	2
DVT/PE	-	-
MACE	1	-
malignancy excl NMSC	-	-
deaths	-	-

SELECT-BEYOND

Event type	upadacitinib, 24-week period # of events	
	15 mg QD	30 mg QD
dose		
N	236	240
SAEs	18	22
opportunistic infections	1	3
herpes zoster	3	7
DVT/PE	3	1
MACE	1	1
malignancy excl NMSC	2	2
deaths	1	1

Note: Data not from head-to-head studies; comparisons could be inaccurate.

Upadacitinib patient numbers refer to the patients initially randomized to drug, 15mg: 164, 30mg: 165, plus the number of placebo patients switched to drug in the second part of the study, 15mg: 72, 30mg: 75, and does not include dropouts, based on the SELECT-BEYOND publication (Genovese et al, Lancet, 2018)